{
    "2021-04-30": [
        [
            {
                "time": "",
                "original_text": "分享 | 如何成功申请突破性治疗药物认定",
                "features": {
                    "keywords": [
                        "突破性治疗",
                        "药物认定"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "泰格医药(300347)：临床试验陆续恢复 收入逐季改善",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "临床试验",
                        "收入改善"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "泰格医药(300347)：业绩略超预期 全年订单饱满",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "业绩超预期",
                        "订单饱满"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "CXO公司2020年成绩单：“药明系”摘得多项桂冠，泰格医药人均创利最高",
                "features": {
                    "keywords": [
                        "CXO",
                        "药明系",
                        "泰格医药",
                        "人均创利"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药“小阳春”行情渐入佳境 医药龙头股票有哪些？",
                "features": {
                    "keywords": [
                        "医药",
                        "小阳春",
                        "龙头股票"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "大和升泰格医药目标至170港元，重申优于大市评级",
                "features": {
                    "keywords": [
                        "大和",
                        "泰格医药",
                        "目标价",
                        "优于大市"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "大和：泰格医药维持跑赢大市评级 目标价升至170港元",
                "features": {
                    "keywords": [
                        "大和",
                        "泰格医药",
                        "跑赢大市",
                        "目标价"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药持仓注重估值和业绩匹配度 继续坚持这些白马龙头股",
                "features": {
                    "keywords": [
                        "医药",
                        "估值",
                        "业绩匹配",
                        "白马龙头"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "大和：上调泰格医药(3347.HK)目标价至170港元 评级“跑赢大市”",
                "features": {
                    "keywords": [
                        "大和",
                        "泰格医药",
                        "上调目标价",
                        "跑赢大市"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "[浙商|孙建] 泰格医药：符合预期，看好2021年收入端加速",
                "features": {
                    "keywords": [
                        "浙商",
                        "泰格医药",
                        "收入端加速"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}